

Special Issue

Bioactive Compounds for Metabolic Syndrome and Type 2 Diabetes

Message from the Guest Editor

Metabolic syndrome is defined as a series of risk factors that commonly cluster together, increasing the risk of both type 2 diabetes and cardiovascular disease. Several factors contribute to the development of metabolic syndrome, including poor diet, physical inactivity, age, and genetics. Despite the range of pharmacotherapies that exist to treat the various risk factors associated with metabolic syndrome, there remains a strong need to identify other bioactive compounds that may contribute towards reducing overall risk. These may be individual dietary components, marine-based compounds or newly identified products. This Special Issue aims to identify and review the latest bioactive compounds that have been demonstrated to have a beneficial effect on metabolic syndrome and its risk factors.

Guest Editor

Dr. Natalie C. Ward

School of Biomedical Sciences and Curtin Health Innovation Research Institute, Curtin University Western Australia, Perth 6102, Australia

Deadline for manuscript submissions

closed (31 March 2018)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/9252

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).